医学
卡铂
肿瘤科
浆液性癌
伊立替康
卵巢
透明细胞癌
内科学
浆液性液体
卵巢癌
紫杉醇
顺铂
化疗
PI3K/AKT/mTOR通路
阶段(地层学)
妇科肿瘤学
BRCA突变
临床试验
妇科
癌症
结直肠癌
细胞凋亡
化学
古生物学
生物
生物化学
作者
Aikou Okamoto,Rosalind Glasspool,Seiji Mabuchi,Noriomi Matsumura,Hiroyuki Nomura,Hiroaki Itamochi,Masashi Takano,Tadao Takano,Nobuyuki Susumu,Daisuke Aoki,Ikuo Konishi,Alan Covens,Jonathan A. Ledermann,Delia Mezzanzanica,Christopher Steer,David Millan,Iain A. McNeish,Jacobus Pfisterer,Sokbom Kang,Laurence Gladieff,Jane Bryce,Amit M. Oza
出处
期刊:International Journal of Gynecological Cancer
[BMJ]
日期:2014-11-01
卷期号:24 (Supp 3): S20-S25
被引量:125
标识
DOI:10.1097/igc.0000000000000289
摘要
Abstract Clear cell carcinoma of the ovary (CCC) is a histologic subtype of epithelial ovarian cancer with a distinct clinical behavior. There are marked geographic differences in the prevalence of CCC. The CCC is more likely to be detected at an early stage than high-grade serous cancers, and when confined within the ovary, the prognosis is good. However, advanced disease is associated with a very poor prognosis and resistance to standard treatment. Cytoreductive surgery should be performed for patients with stage II, III, or IV disease. An international phase III study to compare irinotecan/cisplatin and paclitaxel/carboplatin as adjuvant chemotherapy for stage IIV CCC has completed enrollment (GCIG/JGOG3017). Considering the frequent PIK3CA mutation in CCC, dual inhibitors targeting PI3K, AKT in the mTOR pathway, are promising. Performing these trials and generating the evidence will require considerable international collaboration.
科研通智能强力驱动
Strongly Powered by AbleSci AI